Rufinamide (Inovelon®▼) in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years and older.

The New Therapies Subgroup discussed the above drug for the indication stated. The recommendation of this subgroup is as follows:*  

The New Therapies Subgroup of the GMMMG considered the use of rufinamide (Inovelon®) in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years and older.

The group recommends that rufinamide (Inovelon®) may be considered for use as adjunctive therapy in patients who have failed treatment with or are intolerant of alternative traditional antiepileptic drugs.

The group noted the severity of the condition and the data showing that rufinamide has been shown to reduce total seizure frequency.

According to set criteria rufinamide was deemed to be a medium priority for funding.

Review date: September 2019

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.
▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.